Literature DB >> 25300862

Atypical manifestations of visceral leishmaniasis in patients with HIV in north Ethiopia: a gap in guidelines for the management of opportunistic infections in resource poor settings.

Ermias Diro1, Johan van Griensven2, Rezika Mohammed3, Robert Colebunders2, Mesfin Asefa4, Asrat Hailu5, Lutgarde Lynen2.   

Abstract

In regions where it is endemic, visceral leishmaniasis is an important opportunistic infectious disease in people living with HIV. Typically, clinical presentation of visceral leishmaniasis includes chronic fever, hepatosplenomegaly, and weight loss. In Leishmania infantum endemic regions in Europe, atypical visceral leishmaniasis presentations have been well documented, with almost every possible organ involved. However, such reports are rare in Leishmania donovani endemic regions such as east Africa. In this Personal View, we describe the various atypical disease presentations in patients screened as part of an HIV and visceral leishmaniasis clinical trial in north Ethiopia, where up to 40% of patients with visceral leishmaniasis are co-infected with HIV. Atypical presentations such as these are not covered in clinical guidelines used in these settings. Apart from the lack of diagnostic facilities, this gap contributes to the underdiagnosis of atypical visceral leishmaniasis, with associated morbidity and mortality. Involvement of clinicians experienced with the management of HIV and visceral leishmaniasis co-infection in the development of HIV clinical guidelines in affected regions is warranted.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25300862     DOI: 10.1016/S1473-3099(14)70833-3

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  15 in total

1.  Antifungal activity of oral (Tragacanth/acrylic acid) Amphotericin B carrier for systemic candidiasis: in vitro and in vivo study.

Authors:  Heba A Mohamed; Rasha R Radwan; Amany I Raafat; Amr El-Hag Ali
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

2.  Tropical Parasitic Infections in Individuals Infected with HIV.

Authors:  Emily E Evans; Mark J Siedner
Journal:  Curr Trop Med Rep       Date:  2017-10-16

Review 3.  Design of amphotericin B oral formulation for antifungal therapy.

Authors:  Min Liu; Meiwan Chen; Zhiwen Yang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 4.  Leishmaniasis-HIV coinfection: current challenges.

Authors:  José Angelo Lauletta Lindoso; Mirella Alves Cunha; Igor Thiago Queiroz; Carlos Henrique Valente Moreira
Journal:  HIV AIDS (Auckl)       Date:  2016-10-07

5.  Does timing of antiretroviral treatment influence treatment outcomes of visceral leishmaniasis in Northwest Ethiopia?

Authors:  Endashaw M Aderie; Ermias Diro; Rony Zachariah; Marcio Silveira da Fonseca; Charles Abongomera; Bethabile L Dolamo; Koert Ritmeijer
Journal:  Trans R Soc Trop Med Hyg       Date:  2017-03-01       Impact factor: 2.184

6.  Malnutrition Aggravates Alterations Observed in the Gut Structure and Immune Response of Mice Infected with Leishmania infantum.

Authors:  Felipe Gaitán-Albarracín; Monica Losada-Barragán; Nathalia Pinho; Renata Azevedo; Jonathan Durães; Juan Sebastián Arcila-Barrera; Rodrigo C Menezes; Fernanda N Morgado; Vinicius de Frias Carvalho; Adriana Umaña-Pérez; Patricia Cuervo
Journal:  Microorganisms       Date:  2021-06-11

7.  Relapse of visceral leishmaniasis in an HIV-infected patient successfully treated with a combination of miltefosine and amphotericin B.

Authors:  Shauna McQuarrie; Ken Kasper; Dana C Moffatt; Daniel Marko; Yoav Keynan
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 Nov-Dec       Impact factor: 2.471

Review 8.  A review of visceral leishmaniasis during the conflict in South Sudan and the consequences for East African countries.

Authors:  Waleed Al-Salem; Jennifer R Herricks; Peter J Hotez
Journal:  Parasit Vectors       Date:  2016-08-22       Impact factor: 3.876

Review 9.  Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.

Authors:  Wim Adriaensen; Thomas P C Dorlo; Guido Vanham; Luc Kestens; Paul M Kaye; Johan van Griensven
Journal:  Front Immunol       Date:  2018-01-12       Impact factor: 7.561

10.  MAPK1 of Leishmania donovani interacts and phosphorylates HSP70 and HSP90 subunits of foldosome complex.

Authors:  Pavneet Kaur; Mansi Garg; Antje Hombach-Barrigah; Joachim Clos; Neena Goyal
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.